Evidence map›Paper›PMID 33950951›Full record

ArticleMedicine2021

A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.

Sachin M Bhagavan, Swathi Beladakere Ramaswamy, Raghav Govindarajan

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Sachin M BhagavanDepartment of Neurology, University of Missouri Health Care, Missouri.ORCID 0000-0003-0425-6292
Swathi Beladakere Ramaswamy
Raghav Govindarajan
His Majesty's Treasury · GBUniversity of Missouri Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMyasthenia gravis (MG) patients are at increased risk of COVID-19 infection and its complications due to chronic immunosuppression. COVID-19 infection can also increase the risk of myasthenia exacerbation. PATIENT CONCERNS: The patient presented with respiratory distress, fever and chills and was diagnosed with COVID-19 pneumonia. His past medical history includes seropositive generalized MG diagnosed in 2019, hypertension, atrial fibrillation and congestive heart failure with reduced ejection failure. DIAGNOSES: Refractory seropositive generalized MG having COVID-19 pneumonia and respiratory failure (needing mechanical ventilation) with sepsis.

interventionUse of intravenous remdesivir and dexamethasone and patient's myasthenic exacerbation (due to COVID-19 and its complications) was successfully treated with plasmapheresis. OUTCOMES: Patient was successfully weaned off ventilator to trach collar and was discharged to inpatient rehabiliation. He was followed up 1 month post hospital discharge and was on trach collar. LESSONS: This case report illustrates early use of the combination therapy might be beneficial in refractory myasthenia gravis cases even with chronic immunosuppression and severe COVID-19 infection.

Indexed as

COVID-19 Drug TreatmentAdenosine MonophosphateAgedAlanineAntiviral AgentsDexamethasoneDrug Therapy, CombinationGlucocorticoidsHumansMaleMyasthenia GravisPlasmapheresisPneumonia, ViralSARS-CoV-2Adenosine MonophosphateAlanineAntiviral AgentsDexamethasoneGlucocorticoidsremdesivir

Identifiers

PMID33950951
PMCPMC8104252
OpenAlexW3158499371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.